Basic Information
RNALocate ID: | RLID:11003990 |
RNA Symbol: | hsa-miR-502-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-502-3p |
RNA ID: | miRBase:MIMAT0004775 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002670 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01002671 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:11003989 | Exosome | B cell line (Raji)|Primary dendritic cells | 21505438 |
RLID:11003991 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11003992 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11003993 | Microvesicle | Plasma | 23077538 |
RLID:11003994 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000207 | Exosome | Blood | |
RLID-D:11000687 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-502-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-55601 |
MNDR | hsa-miR-502-3p | Ovarian clear cell carcinoma | MNDR-E-MI-55602 |
MNDR | hsa-miR-502-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-55603 |
MNDR | hsa-miR-502-3p | Lymphoma | MNDR-E-MI-55604 |
MNDR | hsa-miR-502-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-55605 |
MNDR | hsa-miR-502-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-55606 |
MNDR | hsa-miR-502-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-55607 |
MNDR | hsa-miR-502-3p | Her2-receptor positive breast cancer | MNDR-E-MI-55608 |
MNDR | hsa-miR-502-3p | Chronic lymphocytic leukemia | MNDR-E-MI-55609 |
MNDR | hsa-miR-502-3p | Gastric cancer | MNDR-E-MI-55610 |
MNDR | hsa-miR-502-3p | Alzheimer disease | MNDR-E-MI-55611 |
MNDR | hsa-miR-502-3p | Bladder cancer | MNDR-E-MI-55612 |
MNDR | hsa-miR-502-3p | Esophageal carcinoma | MNDR-E-MI-55613 |
MNDR | hsa-miR-502-3p | Dysautonomia familial | MNDR-E-MI-55614 |
MNDR | hsa-miR-502-3p | Seizures | MNDR-E-MI-55615 |
MNDR | hsa-miR-502-3p | Cardiovascular disease | MNDR-E-MI-55616 |
MNDR | hsa-miR-502-3p | Lung cancer | MNDR-E-MI-55617 |
MNDR | hsa-miR-502-3p | Parkinson disease | MNDR-E-MI-55618 |
MNDR | hsa-miR-502-3p | Breast cancer | MNDR-E-MI-55619 |
MNDR | hsa-miR-502-3p | Pancreatic cancer | MNDR-E-MI-55620 |
MNDR | hsa-miR-502-3p | Nephroblastoma | MNDR-E-MI-55621 |
MNDR | hsa-miR-502-3p | Colon cancer | MNDR-E-MI-55622 |
MNDR | hsa-miR-502-3p | Familial ovarian cancer | MNDR-E-MI-55623 |
MNDR | hsa-miR-502-3p | Kidney cancer | MNDR-E-MI-55624 |
MNDR | hsa-miR-502-3p | Glioblastoma | MNDR-E-MI-55625 |
MNDR | hsa-miR-502-3p | Astrocytoma | MNDR-E-MI-55626 |
MNDR | hsa-miR-502-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-55627 |
MNDR | hsa-miR-502-3p | Gastric adenocarcinoma | MNDR-E-MI-55628 |
MNDR | hsa-miR-502-3p | Cervical squamous cell carcinoma | MNDR-E-MI-55629 |
MNDR | hsa-miR-502-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-55630 |
MNDR | hsa-miR-502-3p | Lung squamous cell carcinoma | MNDR-E-MI-55631 |
MNDR | hsa-miR-502-3p | Lung adenocarcinoma | MNDR-E-MI-55632 |
MNDR | hsa-miR-502-3p | Adrenocortical carcinoma | MNDR-E-MI-55633 |
MNDR | hsa-miR-502-3p | Thyroid carcinoma | MNDR-E-MI-55634 |
MNDR | hsa-miR-502-3p | Ovarian carcinoma | MNDR-E-MI-55635 |
MNDR | hsa-miR-502-3p | Bladder urothelial carcinoma | MNDR-E-MI-55636 |
MNDR | hsa-miR-502-3p | Pancreatic adenocarcinoma | MNDR-E-MI-55637 |
MNDR | hsa-miR-502-3p | Carcinoma renal cell | MNDR-E-MI-55638 |
MNDR | hsa-miR-502-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-55639 |
MNDR | hsa-miR-502-3p | Renal clear cell carcinoma | MNDR-E-MI-55640 |
MNDR | hsa-miR-502-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-55641 |
MNDR | hsa-miR-502-3p | Hepatocellular carcinoma | MNDR-E-MI-55642 |
MNDR | hsa-miR-502-3p | Familiar ovarian carcinoma | MNDR-E-MI-55643 |
MNDR | hsa-miR-502-3p | B-cell lymphoma | MNDR-E-MI-55644 |
MNDR | hsa-miR-502-3p | Rheumatoid arthritis | MNDR-E-MI-55645 |
MNDR | hsa-miR-502-3p | Retinoblastoma | MNDR-E-MI-55646 |
MNDR | hsa-miR-502-3p | Hodgkin lymphoma | MNDR-E-MI-55647 |
MNDR | hsa-miR-502-3p | Crohn disease | MNDR-E-MI-55648 |
MNDR | hsa-miR-502-3p | Neuromyelitis optica | MNDR-E-MI-55649 |
MNDR | hsa-miR-502-3p | Colorectal cancer | MNDR-E-MI-55650 |
MNDR | hsa-miR-502-3p | Nasopharynx carcinoma | MNDR-E-MI-55651 |
MNDR | hsa-miR-502-3p | Ependymoma | MNDR-E-MI-55652 |
MNDR | hsa-miR-502-3p | Nasopharyngeal cancer | MNDR-E-MI-55653 |
MNDR | hsa-miR-502-3p | Hypersomnolence idiopathic | MNDR-E-MI-55654 |
MNDR | hsa-miR-502-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-55655 |
MNDR | hsa-miR-502-3p | Stroke lacunar | MNDR-E-MI-55656 |
MNDR | hsa-miR-502-3p | Breast cancer her3+ negative | MNDR-E-MI-55657 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | B4GALT5 | Homo sapiens | RR00208370 |
TOP